Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Her diagnosis was "a direct and proximate result of Ms Cartwright's inhalation and ingestion of asbestos contained within the J&J products," it alleged. Johnson & Johnson has denied the ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Johnson & Johnson “should have known that the J&J Products contained harmful, deleterious, carcinogenic and inherently dangerous asbestos dust and fibers” and the products reportedly did not ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) on January 6 and set a price ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

The global bone growth products market report includes exclusive data on 30 vendors. The market is highly competitive, with global players like Medtronic, Johnson & Johnson, Stryker, and Zimmer ...

A class action has been filed against Johnson & Johnson accusing it of selling medicines known to be ineffective. If the action is successful, anyone who bought the products in question since 2005 ...

Johnson & Johnson (JNJ ... Shares of this world's biggest maker of health care products have returned -6.2% over the past month versus the Zacks S&P 500 composite's +1.1% change.